Q4 2025 SCHOTT Pharma AG & Co KgaA Earnings Call Transcript
Key Points
- Schott Pharma AG & CO KGaA (WBO:1SXP) achieved continued revenue growth and high profitability levels, meeting their full-year targets for fiscal year 2025.
- The company generated 57% of total revenues from high-value solutions (HVS), demonstrating progress towards their midterm ambition.
- Significant advancements were made in global expansion, with increased production capacities and the introduction of newly developed and commercialized products.
- The innovation pipeline is strong, positioning the company to capitalize on emerging opportunities and foster sustainable growth.
- Leadership succession has been concluded, providing clarity and confidence for the next phase of growth, with Christian Mias appointed as CEO from May 2026.
- The company faces a challenging market environment with a revised forecast from a key customer leading to lower demand for glass syringes in fiscal year 2026.
- There is a decline in mRNA vaccination revenues, impacting the polymer syringe business.
- The EBITDA margin for fiscal year 2026 is expected to be affected by product mix effects, temporary underutilization of DDS capacities, and ramp-up costs for new factories.
- The company anticipates a 'bridge year' in 2026 with moderate growth, reflecting a more balanced view of current market dynamics.
- Geopolitical shifts are influencing global supply chains, creating new uncertainties that require agility and resilience.
Good morning, ladies and gentlemen. Thank you for joining our earnings call for the fiscal year 2025. My name is Tobias Erfurth, and I'm Head of Investor Relations. It's my pleasure to guide you through today's call.
With me in the room are our CEO, Andreas Reisse; and our CFO, Reinhard Mayer. Andreas will kick off by sharing the key business and financial highlights of SCHOTT Pharma in the fiscal year 2025. He will also provide an update on our growth strategy, including our achievements in innovation and expansion this year. Following this, Reinhard will take us through our financials. He will also present our financial guidance for the fiscal year 2026, while Andreas will comment on the new midterm guidance after 2026. As always, the presentation will be followed by a Q&A session.
Before we begin, slide 2, I would like to remind all participants to take a moment to review our disclaimer. Please note that we walk -- as we talk about the fiscal year 2025, we are referring to the period from October 1 to September
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
